Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreBringing together unparalleled healthcare data, advanced analytics, innovative technologies, and healthcare expertise to create intelligent connections that speed the development and commercialization of innovative medicines to improve patient lives.
Learn MoreAccelerate digital innovation to enable smarter decisions that reduce cost, modernize patient and consumer engagement, and improve health outcomes.
Learn MoreYour world is unique – and quite different from pharma. In the U.S., decision-making has shifted from individual physicians to integrated networks--GPOs, IDNs and payers. These groups have heightened the focus on proving your solution’s value, demanding outcomes analyses and putting pressure on pricing.
Learn MoreFor government agencies and organizations at every level—from federal or national to regional and local—Big Data can have a huge impact on public health.
Learn MoreA curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREGet the latest insights on our life sciences, healthcare, and medical technology solutions in the United States. Follow our blog today!
LEARN MOREYou don’t need me to tell you: It’s harder than ever for commercial teams to get access to healthcare providers for face-to-face promotion. That was the case before the COVID-19 pandemic, and the global health crisis only led to further restrictions on in-person access. In fact, IQVIA research has shown that as of June 25, 2021, in-person details were 57% of the pre-COVID-19 baseline.
As a result, many life sciences companies began investing significant resources in non-personal promotions, often using digital technologies to deliver these communications. Yet no one has endless resources to throw at every sales and marketing channel for every HCP. Instead, commercial teams are facing this critically important question: What’s the right combination of personal and non-personal promotion for each HCP – and how should we tweak that combination over time?
Read more - Three Ways to Optimize Promotions and Drive Dynamic Deployment